Wherefore interferon?

Journal of Leukocyte Biology

Volumn 61, Issue 5, 1997, Pages 567-574

  Gresser, Ion ^a  

^a CNRS   (France)

Author keywords

antitumor activity; clinical use; effect on immune system; induction of disease

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER; GENERAL ASPECTS OF DISEASE; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

EID: 0031010453     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.61.5.567     Document Type: Review

References (109)

1. Gresser, I. (1975) Interferon therapy: Obvious and not so obvious applications. Acta Med. Scand. 197, 49-53.
2. Gresser, I. (1977) On the varied biologic effects of interferon. Cell. Immunol. 34, 406-415.
3. Isaacs, A., Lindenmann, J. (1957) Virus interference. I. The interferon. Proc. R. Soc. London Ser. B. 147, 258-267.
4. Henle, W. (1950) Interference phenomena between animal viruses: A review. J. Immunol. 64, 203-236.
5. Andrewes, C. H. (1942) Interference by one virus with the growth of another in tissue-culture. Br. J. Exp. Pathol. 23, 214-220.
6. Lennette, E. H., Koprowski, H. (1946) Interference between viruses in tissue culture. J. Exp. Med. 83, 195-219.
7. Gard, S. (1944) Tissue immunity in mouse poliomyelitis. Acta Med. Scand. 119, 27-46.
8. Nagano, Y., Kojima, Y. (1958) Inhibition de l'infection vaccinale par un facteur liquide dans le tissu infecté par le virus homologue. C. R. Soc. Biol. 152, 1627-1629.
9. Ho, M., Enders, J. F. (1959) An inhibitor of viral activity appearing in infected cell cultures. Proc. Natl. Acad. Sci. USA 45, 385-389.
10. Gresser, I., Coppey, J., Falcoff, E., Fontaine, D. (1967) Interferon and murine leukemia. I. Inhibitory effect of interferon preparations on the development of Friend leukemia in mice. Proc. Soc. Exp. Biol. Med. 124, 84-91.
11. Gresser, I., Berman, L., De Thé, G., Brouty-Boyé, D., Coppey, J., Falcoff, E. (1968) Interferon and murine leukemia. V. Effect of interferon preparations on the evolution of Rauscher disease in mice. J. Natl. Cancer Inst. 41, 505-522.
12. Gresser, I., Coppey, J., Fontaine-Brouty-Boyé, D., Falcoff, R., Falcoff, E., Zajdela, F. (1967) Interferon and murine leukemia. III. Efficacy of interferon preparations administered after inoculation of Friend virus. Nature 215, 174-175.
13. Hilleman, M. R. (1963) Interferon in prospect and perspective. J. Cell. Comp. Physiol. 62, 337-351.
14. Hilleman, M. R. (1965) Immunologic, chemotherapeutic and interferon approaches to control of viral disease. Am. J. Med. 5, 751-766.
15. Lockart, R. Z., Jr. (1967) Recent progress in research on interferons. Progr. Med. Virol. 9, 451-475.
16. Gresser, I., Coppey, J., Bourali, C. (1969) Interferon and murine leukemia. VI. The effect of interferon preparations on the lymphoid leukemia of AKR mice. J. Natl. Cancer Inst. 43, 1083-1089.
17. Gresser, I., Coppey, J., Fontaine-Brouty-Boyé, D., Falcoff, E., Falcoff, R., Zajdela, F., Bourali, C., Thomas, M-T. (1967) The effect of interferon preparations on Friend leukemia in mice. Ciba Symposium on Interferon, London: J. and A. Churchill, 240-248.
18. Gresser, I., Bourali, C., Lévy, J-P., Fontaine-Brouty-Boyé, D., Thomas, M-T. (1969) Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc. Natl. Acad. Sci. USA 63, 51-57.
19. Gresser, I., Bourali, C. (1969) Exogenous interferon and inducers of interferon in the treatment of BALB/c mice inoculated with RC19 tumor cells. Nature 223, 844-845.
20. Gresser, I., Bourali, C. (1970) Antitumor effects of interferon preparations in mice. J. Natl. Cancer Inst. 45, 365-376.
21. Gresser, I. (1972) Antitumor effects of interferon. In Advances in Cancer Research (G. Klein and S. Weinhouse, eds.) New York: Academic Press, 16, 91-141.
22. Gresser, I. (1977) Antitumor effects of interferon. In Cancer -Comprehensive Treatise. Vol. 5, Chemotherapy (F. Becker, ed.) New York: Plenum, 521-571.
23. Gresser, I. (1982) How does interferon inhibit tumor growth? Phil. Trans. R. Soc. Lond. Ser. B 299, 69-76.
24. Gresser, I. (1985) How does interferon inhibit tumor growth? In Interferon 6 (I. Gresser, ed.) New York: Academic, 93-126.
25. Gresser, I. (1989) Antitumor effects of interferon. Acta Oncol. 28, 347-353.
26. Affabris, E., Jemma, C., Rossi, G. B. (1982) Isolation of interferon-resistant variants of Friend erythroleukemia cells: effect of interferon and ouabain. Virol. 120, 441-452.
27. Tovey, M. G., Begon-Lours, J., Gresser, I. (1974) A method for the large scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809-815.
28. De Maeyer, J., Tovey, M. G., Gresser, I., De Maeyer, E. (1978) Purification of mouse interferon by sequential affinity chromatography on poly (U) and antibody-agarose columns. Nature 271, 622-625.
29. Belardelli, F., Gresser, I., Maury, C., Maunoury, M-T. (1982) Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int. J. Cancer 30, 813-820.
30. Belardelli, F., Gresser, I., Maury, C., Duvillard, P., Prade, M., Maunoury, M-T. (1983) Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously. Int. J. Cancer 31, 649-653.
31. Dvorak, H., Gresser, I. (1989) Microvascular injury in the pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 81, 497-502.
32. Sidky, Y. A., Borden, E. C. (1987) Inhibition of angiogenesis by interferons: Effects on tumor-and lymphocyte-induced vascular responses. Cancer Res. 47, 5155-5161.
33. Brouty-Boyé, D., Zetter, B. (1980) Inhibition of cell motility by IFN. Science 208, 516-518.
34. Gresser, I., Maury, C., Woodrow, D., Moss, J., Gräutter, M. G., Vignaux, F., Belardelli, F., Maunoury, M-T. (1988) Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int. J. Cancer 41, 135-142.
35. Gresser, I., Kaido, T., Maury, C., Woodrow, D., Moss, J., Belardelli, F. (1994) Interaction of IFN α/β with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases in mice. Int. J. Cancer 57, 604-611.
36. Gresser, I., Carnaud, C., Maury, C., Sala, A., Eid, P., Woodrow, D., Maunoury, M-T., Belardelli, F. (1991) Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α/β treatment in mice. J. Exp. Med. 173, 1193-1203.
37. Gresser, I., Maury, C., Belardelli, F., Maunoury, M-T., Machover, D. (1988) Mouse interferon α/β is more effective than single agent chemotherapy in increasing the survival time of mice after intravenous inoculation of Friend erythroleukemia cells. J. Natl. Cancer Inst. 80, 126-131.
38. Kaido, T., Gresser, I., Maury, C., Maunoury, M-T., Vignaux, F., Belardelli, F. (1993) Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN α/β therapy of Friend erythroleukemia visceral metastases. Int. J. Cancer 54, 475-481.
39. + T-cells and IFN α/β. Int. J. Cancer 57, 538-543.
40. + T lymphocytes are required for the synergistic action of IFN α/β and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res. 55, 6133-6139.
41. Gresser, I. (1982) Can interferon induce disease? In Interferon 4 (I. Gresser, ed.) New York: Academic Press, 95-127.
42. Gresser, I., Tovey, M. G., Maury, C., Chouroulinkov, I. (1975) Lethality of interferon preparations for new-born mice. Nature 258, 76-78.
43. Gresser, I., Aguet, M., Morel-Maroger, L., Woodrow, D., Puvion-Dutilleul, F., Guillon, J-C., Maury, C. (1981) Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am. J. Pathol. 102, 396-402.
44. Zwingelstein, G., Meister, R., Malak, N. A., Maury, C., Gresser, I. (1985) Interferon alters the composition and metabolism of lipids in the liver of suckling mice. J. Interferon Res. 5, 315-325.
45. Zwingelstein, G., Brichon, G., Meister, R., Maury, C., Gresser, I. (1987) Interferon α/β induces changes in the metabolism of polyenoic phospholipids and diacylglycerols in the livers of suckling mice. Lipids 22, 736-743.
46. Gresser, I., Morel-Maroger, L., Maury, C., Tovey, M. G., Pontillon, F. (1976) Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263, 420-422.
47. Morel-Maroger, L., Sloper, J. C., Vinter, J., Woodrow, D., Gresser, I. (1978) An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab. Invest. 39, 513-522.
48. Woodrow, D., Moss, J., Gresser, I. (1984) Interferon induces pulmonary cysts in A2G mice. Proc. Natl. Acad. Sci. USA 81, 7937-7940.
49. Rivière, Y., Gresser, I., Guillon, J-C., Bandu, M-T., Ronco, P., Morel-Maroger, L., Verroust, P. (1980) Severity of LCM virus disease in different strains of suckling mice correlates with increasing amounts of endogenous interferon. J. Exp. Med. 152, 633-640.
50. Rivière, Y., Gresser, I., Guillon, J-C., Tovey, M. G. (1977) Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. Proc. Natl. Acad. Sci. USA 74, 2135-2139.
51. Gresser, I., Morel-Maroger, L., Verroust, P., Rivière, Y., Guillon, J-C. (1978) Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA 75, 3413-3416.
52. Ronco, P., Woodrow, D., Rivière, Y., Moss, J., Verroust, P., Guillon, J-C., Gresser, I., Sloper, J., Morel-Maroger, L. (1980) Further studies on the inhibition of lymphocyte choriomeningitis-induced glomerulonephritis by anti-interferon globulin. Circulating immune complexes and ultrastructural studies. Lab. Invest. 43, 37-46.
53. Stewart, T. A., Hultgren, B., Huang, X., Pitts-Meek, S., Hully, J., MacLachlan, N. J. (1993) Induction of type I diabetes by interferon-α in transgenic mice. Science 260, 1942-1946.
54. Huang, X., Yuan, J., Goddard, A., Foulis, A., James, R. F. L., Lernmark, A., Pujol-Borrell, R., Rabinovitch, A., Somoza, N., Stewart, T. A. (1995) Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44, 658-664.
55. Foulis, A. K. (1996) The pathology of the endocrine pancreas in type I (insulin-dependent) diabetes mellitus. APMIS 104, 161-167.
56. Belardelli, F., Gresser, I. (1996) The neglected role of type I interferon in the T cell response: implications for its clinical use. Immunol. Today 17, 369-372.
57. Gresser, I., De Maeyer-Guignard, J., Tovey, M. G., De Maeyer, E. (1979) Electrophoretically pure mouse interferon exerts multiple biologic effects. Proc. Natl. Acad. Sci. USA 76, 5308-5312.
58. Isaacs, A. (1961) Interferon and recovery from virus infections. Bull. Schweiz. Akad. Med. Wiss. 17, 477-484.
59. Fauconnier, B. (1971) Effet du sérum anti-interféron sur la pathogénicité virale expérimentale in vivo. Path. Biol. 19, 575-578.
60. Gresser, I., Tovey, M. G., Bandu, M-T., Maury, C., Brouty-Boyé, D. (1976) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144, 1305-1315.
61. Gresser, I., Tovey, M. G., Maury, C., Bandu, M-T. (1976) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J. Exp. Med. 144, 1316-1323.
62. Chong, K. T., Gresser, I., Mims, C. A. (1983) Interferon as a defense mechanism in mouse cytomegalovirus infection. J. Gen. Virol. 64, 461-464.
63. Gresser, I., Maury, C., Kress, C., Blangy, D., Maunoury, M-T. (1979) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. VI. Polyoma virus infection. Int. J. Cancer 24, 178-183.
64. Lindenmann, J., Lance, C. A., Hobson, D. (1963) The resistance of A2G mice to myxoviruses. J. Immunol. 90, 942-951.
65. Lindenmann, J. (1964) Inheritance of resistance to influenza virus in mice. Proc. Soc. Exp. Biol. Med. 116, 506-509.
66. Haller, O., Arnheiter, H., Lindenmann, J. (1976) Genetically determined resistance to infection by hepatotropic influenza A virus in mice: Effect of immunosuppression. Infect. Immun. 13, 844-854.
67. Haller, O., Arnheiter, H., Gresser, I., Lindenmann, J. (1979) Genetically determined interferon dependent resistance to influenza virus in mice. J. Exp. Med. 149, 601-612.
68. Haller, O., Arnheiter, H., Lindenmann, J., Gresser, I. (1980) Host gene influences sensitivity to interferon action selectively for influenza virus. Nature 283, 660-662.
69. Virelizier, J-L., Gresser, I. (1978) Role of interferon in the pathogenesis of viral diseases of mice as demonstrated by the use of anti-interferon serum. V. Protective role in mouse hepatitis virus type 3 infection of susceptible and resistant strains of mice. J. Immunol. 120, 1616-1619.
70. Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., Aguet, M. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921.
71. Van Den Broek, M. F., Müller, U., Huang, S., Zinkernagel, R. M., Aguet, M. (1995) Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148, 5-18.
72. Kimura, T., Nakayama, K., Penninger, J., Kitagawa, M., Harada, H., Matsuyama, T., Tanaka, N., Kamijo, R., Vilcek, J., Mak, T. W., Taniguchi, T. (1994) Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 264, 1921-1924.
73. Meraz, M. A., White, J. M., Sheelan, K. C. F., Bach, E. A., Rodig, J. K., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., Schreiber, R. D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442.
74. Durbin, J. E., Hackenmiller, R., Simon, C., Levy, D. E. (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443-450.
75. Kimura, T., Kadokawa, Y., Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Tarutani, M., Tan, R. S-P., Takasugi, T., Matsuyama, T., Mak, T. W., Noguchi, S., Taniguchi, T. (1996) Essential and non-redundant roles of p48 (ISGF3γ) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1, 115-124.
76. Bocci, V. (1985) The physiological interferon response. Immunol. Today 6, 7-9.
77. Khan, N. U-D., Pulford, K. A. F., Farquharson, M. A., Howatson, A., Stewart, C., Jackson, R., McNicol, A. M., Foulis, A. K. (1989) The distribution of immunoreactive interferon-alpha in normal human tissues. Immunol. 66, 201-206.
78. Howastson, A. G., Farquharson, M., Meager, A., McNicol, A. M., Foulis, A. K. (1988) Localization of α-interferon in the human feto-placental unit. J. Endocrinol. 119, 531-534.
79. Belardelli, F., Vignaux, F., Proietti, E., Gresser, I. (1984) Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis and encephalomyocarditis virus. Proc. Natl. Acad. Sci. USA 81, 602-606.
80. Gresser, I., Vignaux, F., Belardelli, F., Tovey, M. G., Maunoury, M-T. (1985) Injection of mice with antibody to mouse interferon α/β decreases the level of 2′-5′ oligo-adenylate synthetase in peritoneal macrophages. J. Virol. 53, 221-227.
81. Paucker, K., Cantell, K., Henle, W. (1962) Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virol. 17, 324-334.
82. Lindahl, P., Leary, P., Gresser, I. (1973) Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc. Natl. Acad. Sci. USA 70, 2785-2788.
83. Lindahl, P., Leary, P., Gresser, I. (1974) Enhancement by interferon of the expression of histocompatibility antigens of mouse lymphoid cells in vitro. Eur. J. Immunol. 4, 779-784.
84. Killander, D., Lindahl, P., Lundin, L., Leary, P., Gresser, I. (1976) Relationship between the enhanced expression of histocompatibility antigens on interferon-treated L 1210 cells and their position in the cell cycle. Eur. J. Immunol. 6, 56-59.
85. Lindahl, P., Gresser, I., Leary, P., Tovey, M. G. (1976) Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc. Natl. Acad. Sci. USA 73, 1284-1287.
86. Vignaux, F., Gresser, I. (1977) Differential effects of interferon on the expression of H-2K, H-2D and Ia antigens on mouse lymphocytes. J. Immunol. 118, 721-723.
87. Zinkernagel, R. M., Doherty, P. C. (1974) Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701-702.
88. Zinkernagel, R. M., Doherty, P. C. (1975) H-2 compatibility requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J. Exp. Med. 141, 1427-1436.
89. Huang, K. Y., Donahoe, R. M., Gordon, F. B., Dressler, H. R. (1971) Enhancement of phagocytosis by interferon-containing preparations. Infect. Immun. 4, 581-588.
90. Tough, D. F., Borrow, P., Sprent, J. (1996) Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science, in press.
91. Von Hoegen, P., Zawatzky, R., Schirrmacher, V. (1990) Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/β. Cell. Immunol. 126, 80-90.
92. Gresser, I., Guy-Grand, D., Maury, C., Maunoury, M-T. (1981) Interferon induces peripheral lymphadenopathy in mice. J. Immunol. 127, 1569-1574.
93. Brodeur, B. R., Merigan, T. C. (1974) Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J. Immunol. 113, 1319-1325.
94. Vignaux, F., Gresser, I., Fridman, W. H. (1980) Effect of virus-induced interferon on the antibody response of suckling and adult mice. Eur. J. Immunol. 10, 767-772.
95. Coutelier, J-P., Van Der Logt, J. T. M., Heessen, F. W. A., Warnier, G., Van Snick, J. (1987) IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165, 64-69.
96. Finkelman, F. D., Svetic, A., Gresser, I., Snapper, C., Holmes, J., Trotta, P. P., Katona, I. M., Gause, W. C. (1991) Regulation by interferon α of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174, 1179-1188.
97. Kerr, I. M., Stark, G. R. (1992) The antiviral effects of the interferons and their inhibition. J. Interferon Res. 12, 237-240.
98. Symons, J. A., Alcami, A., Smith, G. L. (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551-560.
99. Gresser, I., Bourali, C., Thomas, M-T., Falcoff, E. (1968) Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus. Proc. Soc. Exp. Biol. Med. 127, 491-496.
100. Gresser, I., Tovey, M. G., Bourali-Maury, C. (1975) Efficacy of exogenous interferon treatment initiated after onset of multiplication of vesicular stomatitis virus in the brains of mice. J. Gen. Virol. 27, 222-233.
101. Lane, H. C., Davey, V., Kovacs, J. A., Feinberg, J., Metcalf, J. A., Herpin, B., Walker, R., Deyton, L., Davey, R. T., Falloon, J., Polis, M. A., Salzman, N. P., Baseler, M., Masur, H., Fauci, A. S. (1990) Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann. Intern. Med. 112, 805-811.
102. Gresser, I. (1991) Antitumor effects of interferons: past, present and future. Br. J. Haematol. 79, 1-5.
103. Strander, H. (1986) Interferon treatment of human neoplasia. Adv. Cancer Res. 46, 1-265.
104. Gutterman, U. (1994) Cytokine therapeutics: Lessons from interferon α. Proc. Natl. Acad. Sci. USA 91, 1198-1205.
105. Strander, H., Cantell, K., Carlstrom, G., Jakobsson, P. A. (1973) Clinical and laboratory investigations on man; systemic administration of potent interferon to man. J. Natl. Cancer Inst. 51, 733-739.
106. Strander, H., Cantell, K., Jakobsson, P. A., Nilsonne, U., Soderberg, G. (1974) Exogenous interferon therapy of osteogenic sarcoma. Acta Orthoped. Scand. 45, 958-967.
107. Cantell, K. (1979) Why is interferon not in clinical use today? In Interferon 1 (I. Gresser, ed.) New York: Academic Press, 1-28.
108. Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., Otani, S. (1995) Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346, 1051-1055.
109. Jacobs, L., Johnson, K. P. (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch. Neurol. 51, 1245-1252.